Pollen K F Yeung
Pharmacy and Medicine
Dalhousie University
Canada
Biography
Dr. Yeung is currently Professor of Pharmacy and Medicine in Dalhousie University (Halifax, NS, Canada). He is an active contributor and consultant for many academic and professional organizations, pharmaceutical industry, granting councils and the Government. He is currently a member on the Board of the Canadian Society of Pharmaceutical Sciences (CSPS), a member on the Editorial Board for Recent Review of Clinical Trials, Drug Metabolism Open Journal, Metabolites and Medical Sciences Monitor. He was the Vice Chair of the Cardiovascular, Pulmonary and Renal (CPR) Section of American Society of Clinical Pharmacology and Therapeutics (ASCPT) from 2006 -2010, a member of the Board of Biotechnology Life Sciences Industry Association in Nova Scotia (BioNova) from 1999 – 2007, Scientific Officer for Nova Scotia Health Research Foundation from 2009 -2011, Member of the Scientific Advisory Committee on Oncology Therapies for Health Canada from 2004 – 2007. Dr. Yeung is currently Professor of Pharmacy and Medicine in Dalhousie University (Halifax, NS, Canada). He is an active contributor and consultant for many academic and professional organizations, pharmaceutical industry, granting councils and the Government. He is currently a member on the Board of the Canadian Society of Pharmaceutical Sciences (CSPS), a member on the Editorial Board for Recent Review of Clinical Trials, Drug Metabolism Open Journal, Metabolites and Medical Sciences Monitor. He was the Vice Chair of the Cardiovascular, Pulmonary and Renal (CPR) Section of American Society of Clinical Pharmacology and Therapeutics (ASCPT) from 2006 -2010, a member of the Board of Biotechnology Life Sciences Industry Association in Nova Scotia (BioNova) from 1999 – 2007, Scientific Officer for Nova Scotia Health Research Foundation from 2009 -2011, Member of the Scientific Advisory Committee on Oncology Therapies for Health Canada from 2004 – 2007.
Research Interest
Pharmacokinetics, Metabolism and Biomarker assessment or Cardiovascular and Anti-Cancer drugs.
